Abciximab
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
danaparoid
Heparinoid anticoagulant (sulfated GAG mixture) · Anticoagulant
START
Prophylaxis 750 units SC BID; HIT: 2250 U IV bolus then taper infusion
TYPICAL MAX
Anti-Xa target 0.5–0.8 IU/mL (HIT)
STOP IF
Major bleeding, HIT cross-reactivity, or epidural haematoma
WATCH
Anti-Xa levels, platelets, renal function, bleeding signs; neuraxial timing
CDSCO approvedATC B01AB09
KDIGO 2024 + manufacturer label
- ONSET
- 30min · IV onset
- PEAK
- 4h · SC Cmax
- t½
- 1d · anti-Xa t½
- DURATION
- 1d · BID
EXCRETION
Renal — largely unchanged
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Acceptable when indicated (used in HIT during pregnancy).
FDA category + note
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AlteplaseSevereDatabaseDDInter
- AnagrelideSevereDatabaseDDInter
Mechanism
Mixture of low-molecular-weight sulfated glycosaminoglycans (heparan/dermatan/chondroitin sulfate) that potentiates antithrombin-mediated inhibition of factor Xa (anti-Xa : anti-IIa ratio ~22:1); minimal cross-reactivity with HIT antibodies — therapeutic option in heparin-induced thrombocytopenia.
Indications
Prophylaxis/treatment of VTE in heparin-induced thrombocytopenia (HIT)VTE prophylaxis (selected European indications)
Dosing
- Adult
- VTE prophylaxis: 750 anti-Xa units SC twice daily. HIT treatment: 2,250 anti-Xa unit IV bolus, then 400 units/h × 4 h, then 300 units/h × 4 h, then 150–200 units/h maintenance (anti-Xa target 0.5–0.8 IU/mL).
- Pediatric
- Specialist (paediatric anticoagulation).
- Renal adjustment
- Caution in severe impairment; level (anti-Xa) monitoring.
- Hepatic adjustment
- Caution; bleeding risk.
- Geriatric
- Higher bleeding risk; assess renal function.
- Max dose
- Per anti-Xa target (HIT) or 750 units SC BID (prophylaxis)
Pharmacokinetics
Onset
Anticoagulation within 30–60 min (IV)
Peak effect
End of infusion / 2–5 h SC
Duration
~24 h (SC prophylactic)
Half-life
Anti-Xa ~24 h
Bioavailability
SC ~100% (anti-Xa)
Protein binding
Low
Metabolism
Minimal metabolism
Excretion
Renal (largely unchanged)
Contraindications
- Severe haemorrhage
- Severe haemorrhagic stroke
- Severe uncontrolled hypertension
- Documented danaparoid hypersensitivity
- Caution: severe renal/hepatic impairment
Side effects
Common
BleedingInjection-site reactionsMild transaminase rise
Serious
- Major bleeding
- Cross-reactivity with HIT antibodies (~10–15% in vitro; clinical significance lower)
- Severe hypersensitivity
- Spinal/epidural haematoma (neuraxial)
Pregnancy & lactation
Pregnancy
Acceptable when indicated (used in HIT during pregnancy).
Lactation
Limited data; minimal milk transfer.
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alteplase
Severe
Database
Clinical effect not specified
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Antithrombin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Iii Human
Severe
Database
Clinical effect not specified
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Argatroban
Severe
Database
Clinical effect not specified
Source: DDInter
Aspirin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Betrixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bivalirudin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Anticoagulant management for dental procedures
ADA_DENTAL · Dentistry · 2015
Infective endocarditis prevention
NICE · Cardiology / Dentistry · 2008
Infective endocarditis prevention
AHA · Cardiology / Dentistry · 2007
Ask House about danaparoid
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20